These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacogenetics of EGFR and VEGF inhibition. Pander J; Gelderblom H; Guchelaar HJ Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885 [TBL] [Abstract][Full Text] [Related]
5. New agents in development for breast cancer. Gao XP; Liu F Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855 [TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. Huang SM; Li J; Harari PM Cancer Chemother Biol Response Modif; 2001; 19():339-52. PubMed ID: 11686022 [No Abstract] [Full Text] [Related]
8. Molecular mechanisms and targeting of colorectal cancer. Vanhoefer U Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005 [TBL] [Abstract][Full Text] [Related]
10. The epidermal growth factor receptor as a target for therapy. Harris AL Cancer Cells; 1990 Oct; 2(10):321-3. PubMed ID: 2282249 [No Abstract] [Full Text] [Related]
11. Monoclonal Antibodies in Cancer--Fourth International Congress. EGFR/HER1 antibodies. 3-6 September 2004, Colorado Springs, CO, USA. Zhu Z IDrugs; 2004 Nov; 7(11):974-6. PubMed ID: 15551165 [No Abstract] [Full Text] [Related]
12. Preface: oncometabolism: a new field of research with profound therapeutic implications. Galluzzi L; Kroemer G Methods Enzymol; 2014; 542():xix-xxiii. PubMed ID: 24862280 [No Abstract] [Full Text] [Related]
13. Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer. Leena Panigrahi L; Samal P; Ranjan Sahoo S; Sahoo B; Pradhan AK; Mahanta S; Rath SK; Arakha M Nanoscale Adv; 2024 Jul; 6(15):3699-3713. PubMed ID: 39050943 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports. Fang SY; Wu CS; Liu YS; Wei KC Medicine (Baltimore); 2019 Nov; 98(47):e18112. PubMed ID: 31764850 [TBL] [Abstract][Full Text] [Related]
15. Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy. Choe R; Durduran T IEEE J Sel Top Quantum Electron; 2012 Jul; 18(4):1367-1386. PubMed ID: 23243386 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Santin AD; Sill MW; McMeekin DS; Leitao MM; Brown J; Sutton GP; Van Le L; Griffin P; Boardman CH Gynecol Oncol; 2011 Sep; 122(3):495-500. PubMed ID: 21684583 [TBL] [Abstract][Full Text] [Related]
17. Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Aggarwal C; Borghaei H Onco Targets Ther; 2009 Feb; 2():251-60. PubMed ID: 20616912 [TBL] [Abstract][Full Text] [Related]
18. Prospect of anticancer therapy. Park HS Cancer Res Treat; 2004 Apr; 36(2):100-2. PubMed ID: 20396548 [No Abstract] [Full Text] [Related]
19. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369 [TBL] [Abstract][Full Text] [Related]